The American Kidney Fund (AKF) announced Momen Abbasi, MD, and Api Chewcharat, MD, as the recipients of its 2025 Clinical Scientist in Nephrology (CSN) fellowship.
For more than 30 years, the CSN program has supported researchers working to improve diagnosis, treatment, and outcomes for patients with chronic kidney disease. The fellowship may be granted annually for up to 2 years and provides a maximum of $90,000 per year toward the fellow’s salary and career development. CSN fellows conduct research and receive advanced training in areas related to the AKF’s vision.
Momen Abbasi
Dr. Abbasi is a nephrology fellow at the University of Illinois Chicago, where he is pursuing an additional nephrology fellowship. He is working to develop and test non-invasive methods for assessing kidney damage with advanced imaging techniques that provide a safer alternative to kidney biopsies.
His research will use artificial intelligence and machine learning to analyze imaging data from kidney functional magnetic resonance imaging scans in individuals with kidney disease. The goal is to identify specific patterns in kidney disease that can help predict which patients are at a higher risk for declining kidney function.
Api Chewcharat
Dr. Chewcharat is a nephrology fellow in the Brigham and Women’s Hospital and Massachusetts General Hospital combined program.
Dr. Chewcharat’s research focuses on kidney disease and cancer, and he is studying whether biomarkers in the blood can be used to detect thrombotic microangiopathy (TA-TMA). TA-TMA is a serious complication that may occur after a stem cell transplant and can cause serious damage to the kidneys.
He is also exploring the possibility of creating a predictive tool to assess which patients with TA-TMA are at high risk for dialysis or death. Facilitating earlier diagnosis and accurate risk assessment may help reduce adverse outcomes and improve patients’ quality of life.
Source: American Kidney Fund
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.